Search Results - Anne‐Emmanuelle Fargeton

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    ELLIPSE Study

    ELLIPSE Study by Sophie Dupuis‐Girod, A. Ambrun, Évelyne Decullier, Géraldine Samson, Adeline Roux, Anne‐Emmanuelle Fargeton, Catherine Rioufol, Vérane Schwiertz, F. Disant, François Chapuis, Yves Donazzolo, Gilles Paintaud, Patrick Edery, Frédéric Faure

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients

    Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients by A Guilhem, Anne‐Emmanuelle Fargeton, Anne-Claire Simon, P. Duffau, Jean‐Robert Harlé, Christian Lavigne, Marie‐France Carette, O Blétry, P. Kaminsky, V. Leguy, Nathalie Lerolle, Dominique Roux, M. Lambert, Thierry Chinet, Delphine Bonnet, Sophie Dupuis‐Girod, Sophie Rivière

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia

    Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia by Sophie Dupuis‐Girod, A. Ambrun, Évelyne Decullier, Anne‐Emmanuelle Fargeton, Adeline Roux, Valentine Bréant, Bettina Colombet, Sophie Rivière, C. Cartier, Pascal Lacombe, Thierry Chinet, Sandra Blivet, J.-H. Blondel, Brigitte Gilbert‐Dussardier, Xavier Dufour, Justin Michel, Jean‐Robert Harlé, P. Dessi, Frédéric Faure

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial

    Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial by Sophie Dupuis‐Girod, Sophie Rivière, Christian Lavigne, Anne‐Emmanuelle Fargeton, Brigitte Gilbert‐Dussardier, Vincent Grobost, V. Leguy‐Seguin, Hélène Maillard, S. Mohamed, Évelyne Decullier, Adeline Roux, Lorraine Bernard, Jean‐Christophe Saurin, N. Saroul, Frédéric Faure, C. Cartier, Romain Altwegg, Laurent Laccourreye, F. Oberti, Marjolaine Beaudoin, C. Dhelens, Céline Desvignes, Nicolas Azzopardi, Gilles Paintaud, Ruben Hermann, Thierry Chinet

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?

    European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)? by Sophie Dupuis‐Girod, Claire L. Shovlin, Anette Drøhse Kjeldsen, Hans‐Jurgen Mager, Carlo Sabbà, Freya Droege, Anne‐Emmanuelle Fargeton, Annette Dam Fialla, S. Gandolfi, Ruben Hermann, Gennaro M. Lenato, Guido Manfredi, Marco C. Post, Catherine Rennie, Patrizia Suppressa, Ulrich Sure, Elisabetta Buscarini, Claudia Crocione, Ria Blom, Luisa M. Botella, Fernando Brocca, Caroline Coxall, Karen T. Druckman, Didier Erasme, Paolo Roberto Federici, Christina Grabowski, Mildred Lundgren, Tone Søderman, Dara Woods

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: